Snapshot · Huberman Lab
Monogamous prairie voles have far more oxytocin receptors in the nucleus accumbens than non-monogamous voles, which explains why they work harder to reunite with a separated mate.
Where this was said
At 21:30 · chapter starts 18:21
Prairie voles are an unlikely star of grief neuroscience, but Huberman makes the case compellingly. Within the same species, some populations are monogamous — bonding for life, raising young together — while others are non-monogamous. When experimenters separate a bonded pair with a physical barrier, the monogamous voles will work intensely to breach it and return to their partner; the non-monogamous voles simply do not. [1] — Andrew Huberman "Monogamous prairie voles, which work frantically to reunite with separated mates, have far more oxytocin receptors in the nucleus accumbens…" 18:20 The neurochemical explanation sits cleanly in the oxytocin receptor data: monogamous voles have far more oxytocin receptors concentrated in the nucleus accumbens, the brain area governing motivation, craving, and pursuit. In these animals, attachment has been wired directly into the reward and drive system in a way that non-monogamous voles' brains have not. Huberman bridges this cleanly to human data: people who experience the most intense grief — the compulsive yearning, the reflexive impulse to reach out to the person — show the same oxytocin receptor pattern in brain imaging studies. The voles are not an analogy; they are a mechanistic preview of what happens in the human brain under grief.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.